These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31177821)

  • 41. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metallic Limus-Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra-Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial.
    Lemos PA; Abizaid AA; Meireles GC; Sarmento-Leite R; Prudente M; Cantarelli M; Dourado AD; Mariani J; Perin MA; Costantini C; Costa RA; Costa JR; Chamie D; Campos CA; Ribeiro E
    Cardiovasc Ther; 2015 Dec; 33(6):367-71. PubMed ID: 26352896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent.
    Clever YP; Cremers B; Speck U; Dietz U; Böhm M; Scheller B
    Catheter Cardiovasc Interv; 2014 Aug; 84(2):323-31. PubMed ID: 23996969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results.
    Ormiston JA; Webster MW; Schwartz RS; Gladding P; Stewart JT; Kay IP; Ruygrok PN; Hatrick R
    JACC Cardiovasc Interv; 2009 Oct; 2(10):1017-24. PubMed ID: 19850264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
    Kufner S; Joner M; Schneider S; Tölg R; Zrenner B; Repp J; Starkmann A; Xhepa E; Ibrahim T; Cassese S; Fusaro M; Ott I; Hengstenberg C; Schunkert H; Abdel-Wahab M; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1332-1340. PubMed ID: 28683939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
    Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE
    JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
    Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
    J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions.
    Moses JW; Weisz G; Mishkel G; Caputo R; O'shaughnessey C; Wong SC; Fischell TA; Mooney M; Williams DO; Popma JJ; Fitzgerald P; Smith S; Kuntz RE; Collins M; Cohen SA; Leon MB
    Catheter Cardiovasc Interv; 2007 Oct; 70(4):505-12. PubMed ID: 17896408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial.
    Yu M; Xu B; Kandzari DE; Wu Y; Yan H; Chen J; Qian J; Qiao S; Yang Y; Gao RL
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):405-11. PubMed ID: 23857821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
    Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schömig A; Kastrati A; Mehilli J;
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):161-6. PubMed ID: 21400652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON).
    Rozenman Y; Witzling V; Tamari I; Turkisher V; Kriviski M; Bode C; Henry P; Teiger E; Cebrian A; Stoll HP; Spaulding C
    EuroIntervention; 2009 Jun; 5(2):219-23. PubMed ID: 19527979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study.
    Sgueglia GA; D'Errico F; Gioffrè G; De Santis A; Summaria F; Piccioni F; Gaspardone A
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):851-858. PubMed ID: 28766881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
    Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.